Yesterday, Aug. 2, 2016, 97 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $43.70 to $50,903,280.00.

Highlighted Stocks Traded by Insiders:

C&F Financial (CFFI) - FREE Research Report

Dillon Larry G, who is Chairman & CEO at C&F Financial, sold 1,840 shares at $45.60 on Aug. 2, 2016. Following this transaction, the Chairman & CEO owned 43,778 shares meaning that the stake was reduced by 4.03% with the 1,840-share transaction.

The shares most recently traded at $45.40, down $0.20, or 0.43% since the insider transaction. Historical insider transactions for C&F Financial go as follows:

  • 4-Week # shares sold: 240
  • 12-Week # shares sold: 4,485
  • 24-Week # shares sold: 5,085

The average volume for C&F Financial has been 12,900 shares per day over the past 30 days. C&F Financial has a market cap of $158.5 million and is part of the financial sector and banking industry. Shares are up 17.15% year-to-date as of the close of trading on Friday.

C&F Financial Corporation operates as a bank holding company for Citizens and Farmers Bank that provides commercial banking services to individuals and businesses. The company operates through three segments: Retail Banking, Mortgage Banking, and Consumer Finance. The stock currently has a dividend yield of 2.79%. The company has a P/E ratio of 12.7. Currently, there are no analysts who rate C&F Financial a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CFFI - FREE

TheStreet Quant Ratings

rates C&F Financial as a

buy

. The company's strengths can be seen in multiple areas, such as its solid stock price performance, increase in net income and growth in earnings per share. We feel its strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full

C&F Financial Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Keryx Biopharmaceuticals (KERX) - FREE Research Report

Holmes Scott A, who is Chief Financial Officer at Keryx Biopharmaceuticals, sold 4,935 shares at $7.36 on Aug. 2, 2016. Following this transaction, the Chief Financial Officer owned 108,557 shares meaning that the stake was reduced by 4.35% with the 4,935-share transaction.

The shares most recently traded at $4.72, down $2.64, or 55.93% since the insider transaction. Historical insider transactions for Keryx Biopharmaceuticals go as follows:

  • 4-Week # shares bought: 5,000
  • 4-Week # shares sold: 2,300
  • 12-Week # shares bought: 5,000
  • 12-Week # shares sold: 3,896
  • 24-Week # shares bought: 5,000
  • 24-Week # shares sold: 13,432

The average volume for Keryx Biopharmaceuticals has been 1.3 million shares per day over the past 30 days. Keryx Biopharmaceuticals has a market cap of $778.8 million and is part of the health care sector and drugs industry. Shares are up 45.74% year-to-date as of the close of trading on Friday.

Keryx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on providing therapies for patients with renal disease in the United States. Currently, there are 7 analysts who rate Keryx Biopharmaceuticals a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on KERX - FREE

TheStreet Quant Ratings

rates Keryx Biopharmaceuticals as a

sell

. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, generally disappointing historical performance in the stock itself and generally high debt management risk. Get the full

Keryx Biopharmaceuticals Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Incyte (INCY) - FREE Research Report

Huber Reid M, who is EVP, Chief Scientific Officer at Incyte, sold 10,000 shares at $87.96 on Aug. 2, 2016. Following this transaction, the EVP, Chief Scientific Officer owned 66,601 shares meaning that the stake was reduced by 13.05% with the 10,000-share transaction.

The shares most recently traded at $90.00, up $2.04, or 2.27% since the insider transaction. Historical insider transactions for Incyte go as follows:

  • 4-Week # shares sold: 786
  • 12-Week # shares sold: 786
  • 24-Week # shares sold: 786

The average volume for Incyte has been 1.1 million shares per day over the past 30 days. Incyte has a market cap of $16.5 billion and is part of the health care sector and drugs industry. Shares are down 16.82% year-to-date as of the close of trading on Friday.

Incyte Corporation focuses on the discovery, development, and commercialization of proprietary therapeutics in oncology. It offers JAKAFI for the treatment of myelofibrosis and polycythemia vera cancers. The company has a P/E ratio of 338.9. Currently, there are 11 analysts who rate Incyte a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on INCY - FREE

TheStreet Quant Ratings

rates Incyte as a

hold

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, notable return on equity and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself, poor profit margins and generally higher debt management risk. Get the full

Incyte Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.